{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Blueprint Medicines Corporation"},"Symbol":{"label":"Symbol","value":"BPMC"},"Address":{"label":"Address","value":"45 SIDNEY STREET, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 374-7580"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants."},"CompanyUrl":{"label":"Company Url","value":"https://www.blueprintmedicines.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Becker Hewes","title":"Chief Medical Officer"},{"name":"Christina Rossi","title":"Chief Operating Officer"},{"name":"Christopher K. Murray","title":"Chief Technical Operations & Quality Officer"},{"name":"Fouad Namouni","title":"President-Research & Development"},{"name":"Janet Loesberg","title":"Senior Vice President-Global Medical Affairs"},{"name":"Kathryn Haviland","title":"President, Chief Executive Officer & Director"},{"name":"Percy H. Carter","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}